ID
37766
Description
Study ID: 104864/627 Clinical Study ID: 104864/627 Study Title: An Open-label, Multicenter, Non-Comparative Phase II Study of the Combination of Intravenous Topotecan and Gemcitabine Administered Once Weekly for Three Weeks Every 28 Days as Second-line Treatment in Patients With Recurrent Platinum Sensitive Ovarian Cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00061308 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Topotecan, Gemcitabine Study Indication: Peritoneal Cancer, Ovarian Cancer, Neoplasms, Ovarian, Fallopian Tube Cancer
Keywords
Versions (2)
- 8/22/19 8/22/19 -
- 8/23/19 8/23/19 -
Copyright Holder
GlaxoSmithKline
Uploaded on
August 22, 2019
DOI
To request one please log in.
License
Creative Commons BY-NC 3.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Intravenous Topotecan and Gemcitabine as Second-line Treatment in Patients With Ovarian Cancer NCT00061308
Screening - Significant Medical/ Surgical History and Physical Examination; History of Ovarian Cancer; Tumor Marker
Description
Administrative
Alias
- UMLS CUI-1
- C1320722
Description
Significant Medical/ Surgical History and Physical Examination
Alias
- UMLS CUI-1
- C0262926
- UMLS CUI-2
- C0489540
- UMLS CUI-3
- C0031809
Description
History of Ovarian Cancer
Alias
- UMLS CUI-1
- C0029925
- UMLS CUI-2
- C0262926
Description
Date of Original Diagnosis
Data type
date
Alias
- UMLS CUI [1]
- C2316983
Description
Date of Relapse
Data type
date
Alias
- UMLS CUI [1,1]
- C0035020
- UMLS CUI [1,2]
- C0011008
Description
(please choose one)
Data type
integer
Alias
- UMLS CUI [1,1]
- C0677930
- UMLS CUI [1,2]
- C0011900
Description
Please record the current TNM stage of the patient
Data type
text
Alias
- UMLS CUI [1]
- C1302362
Description
(please choose one) NOTE: Patient is ONL Y eligible if she is stage IIIB, IIIC or IV.
Data type
integer
Alias
- UMLS CUI [1]
- C0450454
Description
Metastatic
Alias
- UMLS CUI-1
- C0027627
Description
Metastasis - Date of Diagnosis
Data type
date
Alias
- UMLS CUI [1,1]
- C2316983
- UMLS CUI [1,2]
- C0027627
Description
Metastasis - Site
Data type
integer
Alias
- UMLS CUI [1]
- C0807944
Description
If other site of metastasis, specify.
Data type
text
Alias
- UMLS CUI [1,1]
- C0807944
- UMLS CUI [1,2]
- C0205394
- UMLS CUI [1,3]
- C2348235
Description
Tumor Marker (CA-125) (7 days prior to Day 1)
Alias
- UMLS CUI-1
- C0474700
- UMLS CUI-2
- C0201549
Similar models
Screening - Significant Medical/ Surgical History and Physical Examination; History of Ovarian Cancer; Tumor Marker
C0489540 (UMLS CUI-2)
C0031809 (UMLS CUI-3)
C0012634 (UMLS CUI [2])
C2603343 (UMLS CUI [3,1])
C3146298 (UMLS CUI [3,2])
C0439849 (UMLS CUI [3,3])
C0600091 (UMLS CUI [1,2])
C0489540 (UMLS CUI-2)
C0031809 (UMLS CUI-3)
C0262926 (UMLS CUI-2)
C0011008 (UMLS CUI [1,2])
C0011900 (UMLS CUI [1,2])
C0027627 (UMLS CUI [1,2])
C0205394 (UMLS CUI [1,2])
C2348235 (UMLS CUI [1,3])
C0201549 (UMLS CUI-2)